摘要
多囊卵巢综合征是一种常见且复杂的内分泌疾病,在育龄期女性中患病人群占1/10左右。多囊卵巢综合征患者中合并超重或肥胖者占比超过一半,且该部分人群代谢和生殖方面问题往往更严重且对治疗反应性较差,该类人群的代谢治疗方案探索成为研究的热点和难点。目前多囊卵巢综合征代谢调整治疗药物主要有二甲双胍、噻唑烷二酮类和阿卡波糖,近年来胰高血糖素样肽-1类似物和钠葡萄糖共转运蛋白-2抑制剂两类降糖药也逐渐被用于超重/肥胖PCOS患者的代谢调整治疗。本文主要就超重/肥胖PCOS患者代谢治疗药物的研究进展作一综述。
Polycystic ovarian syndrome (PCOS) is a common and complex reproductive endocrine disorder during the childbearing age in female with a prevalence of about 10%. Overweight and obesity are common comorbidities among females with PCOS, who account for more than 50%. Overweight/ Obese patients often have worse symptoms and are less responsive to treatment. Seeking more ef-fective treatment means in metabolic dysfunctions and reproductive abnormalities for these people is a hotspot and difficult point in medical research nowadays. There are three main types of antidi-abetic drugs that are used to treat PCOS, including metformin, thiazolidinedione and acarbose. Re-cently, glucagon-like peptide 1 (GLP-1) analogues and sodium-glucose co-transporter-2 (SGLT-2) in-hibitors are progressively used in the treatment of overweight/obese patients with PCOS. This re-view article aims to summarize the recent development of antidiabetic drugs in overweight/ obese patients with PCOS.
出处
《临床医学进展》
2023年第9期13901-13907,共7页
Advances in Clinical Medicine
